BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Oct 3, 2016
Finance

ASH and others

...III data 4Q16 TaiGen Biopharmaceuticals Holdings Ltd. (TPEx:4157) / Zhejiang Medicine Co. Ltd. (Shanghai:600216) IV Taigexyn...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...with constipation (IBS-C) Ph III data; submit NDA 3Q16; YE16 TaiGen Biopharmaceuticals Holdings Ltd. (TPEx:4157) Taigexyn...
BioCentury | Jul 11, 2016
Finance

Shedding red

...patients TaiGen Biopharmaceuticals Holdings Ltd. (TPEx:4157) / Zhejiang Medicine Co. Ltd. (Shanghai:600216) China approves antibiotic Taigexyn...
BioCentury | Jun 20, 2016
Clinical News

Taigexyn nemonoxacin regulatory update

...The China FDA approved TaiGen’s oral Taigexyn nemonoxacin, a non-fluorinated quinolone antibiotic topoisomerase inhibitor. Taigexyn is...
...for IV Taigexyn . TaiGen Biopharmaceuticals Holdings Ltd. (TPEx:4157), Taipei, Taiwan Product: Taigexyn nemonoxacin ( oral nemonoxacin...
...TaiGen Biopharmaceuticals Holdings Ltd. (TPEx:4157), Taipei, Taiwan Product: Taigexyn nemonoxacin ( oral nemonoxacin ) ( TG-873870...
BioCentury | Jun 16, 2016
Company News

CFDA approves TaiGen antibiotic

...TaiGen Biopharmaceuticals Holdings Ltd. (TPEx:4157) said China FDA approved Taigexyn nemonoxacin, a non-fluorinated quinolone antibiotic topoisomerase...
...the agency announced self-inspection requirements for clinical data (see BioCentury Extra, July 29, 2015) . Taigexyn...
...infections (ABSSSIs). Zhejiang Medicine Co. Ltd. (Shanghai:600216) has Taigexyn's commercialization rights in China. TaiGen said Taigexyn...
BioCentury | Dec 7, 2015
Clinical News

Nemonoxacin: Phase III data

...Phase III TG-873870-C-6 trial in 525 patients with CAP showed that once-daily 500 mg IV Taigexyn...
...TaiGen plans to submit an NDA to the China Food and Drug Administration (CFDA) for Taigexyn...
...product in Taiwan to treat community-acquired bacterial pneumonia (CABP). TaiGen has exclusive, worldwide rights to Taigexyn...
BioCentury | Dec 4, 2015
Clinical News

TaiGen prepping NDA in China for antibiotic

...quinolone antibiotic topoisomerase inhibitor. TaiGen markets an oral formulation of the product in Taiwan as Taigexyn...
BioCentury | Aug 3, 2015
Finance

Taiwan's post-bubble prognosis

...a postmoney valuation of NT$34.8 billion ($1.1 billion). Two months later, Taiwan approved TaiGen's oral Taigexyn...
...our current valuation we are hoping to get experienced investors coming in." In addition to Taigexyn...
...$569.5 million) from its January 2014 IPO valuation of NT$34.8 billion ($1.1 billion). The biotech's Taigexyn...
BioCentury | Jan 1, 2015
Top Story

Taiwan, China embark on cross-strait clinical studies

...Taiwan of its oral Taigexyn nemonoxacin , a non-fluorinated quinolone antibiotic topoisomerase inhibitor. In March, Taigexyn...
...and acute bacterial skin and skin structure infections (ABSSSIs). TaiGen has exclusive, worldwide rights to Taigexyn...
Items per page:
1 - 10 of 30